Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis

  • Shipra Grover
  • , Curtis A Engelhart
  • , Esther Pérez-Herrán
  • , Wei Li
  • , Katherine A Abrahams
  • , Kadamba Papavinasasundaram
  • , James M Bean
  • , Christopher M Sassetti
  • , Alfonso Mendoza-Losana
  • , Gurdyal S Besra
  • , Mary Jackson
  • , Dirk Schnappinger

Research output: Contribution to journalArticlepeer-review

Abstract

MmpL3, an essential mycolate transporter in the inner membrane of Mycobacterium tuberculosis (Mtb), has been identified as a target of multiple, chemically diverse antitubercular drugs. However, several of these molecules seem to have secondary targets and inhibit bacterial growth by more than one mechanism. Here, we describe a cell-based assay that utilizes two-way regulation of MmpL3 expression to readily identify MmpL3-specific inhibitors. We successfully used this assay to identify a novel guanidine-based MmpL3 inhibitor from a library of 220 compounds that inhibit growth of Mtb by largely unknown mechanisms. We furthermore identified inhibitors of cytochrome bc 1 -aa 3 oxidase as one class of off-target hits in whole-cell screens for MmpL3 inhibitors and report a novel sulfanylacetamide as a potential QcrB inhibitor.

Original languageEnglish
JournalACS Infectious Diseases
DOIs
Publication statusE-pub ahead of print - 15 Dec 2020

Fingerprint

Dive into the research topics of 'Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this